These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15554754)

  • 1. Prophylactic antipsychotics: do they keep you from catching schizophrenia?
    Stahl SM
    J Clin Psychiatry; 2004 Nov; 65(11):1445-6. PubMed ID: 15554754
    [No Abstract]   [Full Text] [Related]  

  • 2. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study.
    Rossi A; Mancini F; Stratta P; Mattei P; Gismondi R; Pozzi F; Casacchia M
    Acta Psychiatr Scand; 1997 Jan; 95(1):40-3. PubMed ID: 9051159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Food and Drug Administration commentary on methodological issues in negative symptom trials.
    Laughren T; Levin R
    Schizophr Bull; 2011 Mar; 37(2):255-6. PubMed ID: 21245124
    [No Abstract]   [Full Text] [Related]  

  • 4. Neurobiology and phenotypic expression in early onset schizophrenia.
    Vyas NS; Patel NH; Puri BK
    Early Interv Psychiatry; 2011 Feb; 5(1):3-14. PubMed ID: 21272270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical antipsychotics and cognition in schizophrenia.
    Sharma T
    Arch Gen Psychiatry; 2002 Jun; 59(6):571-2; author reply 573-5. PubMed ID: 12044209
    [No Abstract]   [Full Text] [Related]  

  • 6. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse.
    Voruganti LN; Heslegrave RJ; Awad AG
    J Nerv Ment Dis; 1997 Jul; 185(7):463-5. PubMed ID: 9240366
    [No Abstract]   [Full Text] [Related]  

  • 7. Another view of therapy for cognition in schizophrenia.
    Carpenter WT; Gold JM
    Biol Psychiatry; 2002 Jun; 51(12):969-71. PubMed ID: 12062880
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug development and the deficit syndrome of schizophrenia.
    Kirkpatrick B; Carpenter WT
    Biol Psychiatry; 1995 Sep; 38(5):277-8. PubMed ID: 7495920
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():35-40. PubMed ID: 9766618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of brain imaging in assessment of cognitive symptoms. Cognitive and emotional impact of antipsychotic drug treatment]].
    Martinot JL; Peretti CS
    Encephale; 2006 Jan; 32 Pt 2():S3-5. PubMed ID: 16800076
    [No Abstract]   [Full Text] [Related]  

  • 11. Atypical antipsychotics in the treatment of schizophrenia during pregnancy and the postpartum.
    Yaeger D; Smith HG; Altshuler LL
    Am J Psychiatry; 2006 Dec; 163(12):2064-70. PubMed ID: 17151155
    [No Abstract]   [Full Text] [Related]  

  • 12. Improvement of cognitive dysfunction after treatment with second-generation antipsychotics.
    Weiss E; Kemmler G; Fleischhacker WW
    Arch Gen Psychiatry; 2002 Jun; 59(6):572-3; author reply 573-5. PubMed ID: 12044210
    [No Abstract]   [Full Text] [Related]  

  • 13. All antipsychotics are equal, but some are more equal than others.
    Volavka J; Citrome L
    J Clin Psychiatry; 2009 Mar; 70(3):429-30. PubMed ID: 19317959
    [No Abstract]   [Full Text] [Related]  

  • 14. Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.
    Purdon SE
    J Psychiatry Neurosci; 2000 Mar; 25(2):108-16. PubMed ID: 10740984
    [No Abstract]   [Full Text] [Related]  

  • 15. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.
    Saavedra-Velez C; Yusim A; Anbarasan D; Lindenmayer JP
    J Clin Psychiatry; 2009 Jan; 70(1):104-12. PubMed ID: 19026265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.
    Velligan DI; Miller AL
    J Clin Psychiatry; 1999; 60 Suppl 23():25-8. PubMed ID: 10625197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Important steps in the development of cognitive-enhancing drugs in schizophrenia.
    Buchanan RW
    Am J Psychiatry; 2006 Nov; 163(11):1867-9. PubMed ID: 17074932
    [No Abstract]   [Full Text] [Related]  

  • 18. Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions.
    Green MF
    Am J Psychiatry; 2007 Jul; 164(7):992-4. PubMed ID: 17606645
    [No Abstract]   [Full Text] [Related]  

  • 19. Atypical antipsychotic drugs improve cognition in schizophrenia.
    Meltzer HY; Sumiyoshi T
    Biol Psychiatry; 2003 Feb; 53(3):265-7; author reply 267-8. PubMed ID: 12559661
    [No Abstract]   [Full Text] [Related]  

  • 20. Cognitive and functional effects of atypical antipsychotic medications.
    Harvey PD
    J Clin Psychiatry; 2006 Oct; 67(10):e13. PubMed ID: 17107236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.